克拉迪宾片对降低复发性复发性多发性硬化症患者的大脑缩的积极影响:一项纵向研究
Anat Achiron1,2, Yehuda Warszawer1, Yael Nissan1
1Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel.
Multiple sclerosis (Houndmills, Basingstoke, England)
|January 28, 2025
概括
口服克拉迪宾治疗显著减少了复发性复发性多发性硬化症 (RRMS) 患者的脑缩. 脑容量损失在开始服用克拉德里宾后两年内稳定,这表明持续的神经保护作用.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大脑体积的变化是多发性硬化症 (MS) 病理学的关键标记.
- 监测大脑缩对于评估复发性复发性多发性硬化症 (RRMS) 的长期治疗效果至关重要.
研究的目的:
- 评估口服克拉迪宾在缓解RRMS患者大脑体积损失方面的长期疗效.
- 评估cladribine在长时间内对大脑缩率的影响.
主要方法:
- 利用FreeSurfer的rec-all临床管道与SynthSeg用于大脑MRI细分.
- 分析了448张102名RRMS患者的MRI扫描,4年5年的时间,使用线性回归.
- 在开始使用克拉德里宾之前和之后,确定了缩率变化断点.
主要成果:
- 在治疗前,在关键区域观察到显著的大脑缩,包括 Thalamus,深灰色物质 (DGM),皮质下灰色物质 (SubGM),大脑白色物质 (CWM) 和大脑帕伦基马 (BP).
- 在克拉迪宾治疗后,检测到缩率的显著变化.
- 治疗开始后,大脑缩率变得无意义,表明稳定.
结论:
- 口服克拉德里宾在高度活跃的RRMS患者中显示出神经保护作用.
- 脑缩稳定在启动克拉德里宾治疗后的两年内实现.
- 克拉德里宾对大脑体积的持续益处在长时间的观察期间显而易见.
相关概念视频
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
01:20Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141